Time-Resolved Fluorescence Anisotropy of HIV-1 Protease Inhibitor Complexes Correlates with Inhibitory Activity
- 13 February 1998
- journal article
- Published by American Chemical Society (ACS) in Biochemistry
- Vol. 37 (9) , 2778-2786
- https://doi.org/10.1021/bi971654w
Abstract
The tryptophan time-resolved fluorescence intensity and anisotropy of the HIV-1 protease dimer is shown to be a quick and efficient method for the conformational characterization of protease inhibitor complexes. Four fluorescence lifetimes were needed to adequately describe the fluorescence decay of the two tryptophan residues, W6 and W42, per protease monomer. As a result of the wavelength dependence of the respective amplitudes, the 2.06 ns and the 4.46 ns decay constants were suggested to be the intrinsic fluorescence lifetimes of the more solvent-exposed W6 and the less exposed W42 residues, respectively. Analysis of the fluorescence anisotropy decay yielded a short correlation time of 250 ps corresponding to local chromophore motions, and a long correlation time of 12.96 ns resulting from overall rotation of the protease enzyme. Fluorescence lifetimes and rotational correlation times changed when inhibitors of the HIV-1 protease were added. The effects of 11 different inhibitors including statine-derived, hydroxyethylamine-derived, and 2 symmetrical inhibitors on the protease fluorescence dynamics were investigated. Inhibitor binding is shown to induce an increase of the mean fluorescence lifetime τmean, an increase of the short rotational correlation time φ1, as well as a decrease of the long rotational correlation time φ2. The mean rotational correlation time φmean was identified as the global dynamic parameter for a given molecular complex, which correlates with the inhibitor dissociation constant Ki, and therefore with the activity of the inhibitor.Keywords
This publication has 17 references indexed in Scilit:
- Inhibitors of Human Immunodeficiency Virus Type 1 Protease Containing 2-Aminobenzyl-Substituted 4-Amino-3-hydroxy-5-phenylpentanoic Acid: Synthesis, Activity, and Oral BioavailabilityJournal of Medicinal Chemistry, 1996
- CONCERTS: Dynamic Connection of Fragments as an Approach to de Novo Ligand DesignJournal of Medicinal Chemistry, 1996
- Toward Improved Anti-HIV Chemotherapy: Therapeutic Strategies for Intervention with HIV InfectionsJournal of Medicinal Chemistry, 1995
- Flexibility and function in HIV-1 proteaseNature Structural & Molecular Biology, 1995
- Inhibitors of HIV-1 Proteinase Containing 2-Heterosubstituted 4-Amino-3-hydroxy-5-phenylpentanoic Acid: Synthesis, Enzyme Inhibition, and Antiviral ActivityJournal of Medicinal Chemistry, 1994
- STRUCTURE-BASED INHIBITORS OF HIV-1 PROTEASEAnnual Review of Biochemistry, 1993
- Synthesis and antiviral activity of a series of HIV-1 protease inhibitors with functionality tethered to the P1 or P1' phenyl designJournal of Medicinal Chemistry, 1992
- Studies on somatostatin with time‐resolved spectroscopy and molecular dynamics simulationsInternational Journal of Peptide and Protein Research, 1990
- Comparison of inhibitor binding in HIV‐1 protease and in non‐viral aspartic proteases: the role of the flapFEBS Letters, 1990
- Ligand binding and protein dynamics: a fluorescence depolarization study of aspartate transcarbamylase from Escherichia coliBiochemistry, 1987